Eagle Pharmaceuticals, Inc. - Understand $egrx stock

$EGRX Market Cap: $11.69 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$257.6M

TTM

Gross Margin

70.86%

TTM

Net Earnings

$11.95M

TTM

Current Assets

$187.3M

Q2 2023

Current Liabilities

$86.63M

Q2 2023

Current Ratio

216.15%

Q2 2023

Total Assets

$404.8M

Q2 2023

Total Liabilities

$152.8M

Q2 2023

Book Value

$252.0M

Q2 2023

Cash

$15.35M

Q2 2023

P/E

0.9783

Dec 02, 2024 EST

Free Cash Flow

-$9.392M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$316.6M	$171.5M	$187.8M	$195.9M	$213.3M	$236.7M	$189.5M	$66.23M	$19.10M	$13.68M	$2.539M	$9.500M
YoY Change	84.56%	-8.66%	-4.13%	-8.17%	-9.88%	24.92%	186.11%	246.76%	39.62%	438.76%	-73.27%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$316.6M	$171.5M	$187.8M	$195.9M	$213.3M	$236.7M	$189.5M	$66.23M	$19.10M	$13.68M	$2.539M	$9.500M
Cost Of Revenue	$94.94M	$31.53M	$33.65M	$47.89M	$42.37M	$33.71M	$35.79M	$15.65M	$11.71M	$7.381M	$3.166M	$1.800M
Gross Profit	$221.7M	$140.0M	$154.2M	$135.0M	$151.4M	$203.0M	$153.7M	$50.58M	$7.385M	$6.298M	-$627.0K	$7.700M
Gross Profit Margin	70.01%	81.62%	82.08%	68.91%	70.97%	85.76%	81.11%	76.37%	38.67%	46.04%	-24.69%	81.05%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$106.6M	$75.32M	$78.60M	$76.37M	$60.51M	$71.42M	$53.33M	$20.17M	$9.326M	$4.958M	$6.399M	$4.600M
YoY Change	41.56%	-4.17%	2.92%	26.21%	-15.27%	33.92%	164.46%	116.22%	88.1%	-22.52%	39.11%
% of Gross Profit	48.1%	53.79%	50.99%	56.57%	39.97%	35.18%	34.7%	39.87%	126.28%	78.72%		59.74%
Research & Development	$34.09M	$51.28M	$30.79M	$36.81M	$44.42M	$32.61M	$28.29M	$27.86M	$16.82M	$9.795M	$12.81M	$8.700M
YoY Change	-33.52%	66.56%	-16.37%	-17.13%	36.23%	15.26%	1.56%	65.65%	71.68%	-23.51%	47.18%
% of Gross Profit	15.38%	36.62%	19.97%	27.27%	29.34%	16.06%	18.41%	55.07%	227.7%	155.53%		112.99%
Depreciation & Amortization	$646.0K	$764.0K	$872.0K	$972.0K	$1.155M	$932.0K	$641.0K	$112.0K	$104.0K	$135.0K	$240.0K	$270.0K
YoY Change	-15.45%	-12.39%	-10.29%	-15.84%	23.93%	45.4%	472.32%	7.69%	-22.96%	-43.75%	-11.11%
% of Gross Profit	0.29%	0.55%	0.57%	0.72%	0.76%	0.46%	0.42%	0.22%	1.41%	2.14%		3.51%
Operating Expenses	$140.7M	$126.6M	$109.4M	$113.2M	$176.7M	$162.7M	$136.1M	$63.67M	$37.86M	$22.13M	$22.37M	$13.30M
YoY Change	11.15%	15.74%	-3.35%	-35.95%	8.59%	19.53%	113.82%	68.18%	71.03%	-1.05%	68.2%
Operating Profit	$80.96M	$2.769M	$32.95M	$21.82M	$36.62M	$73.99M	$53.35M	$2.560M	-$18.76M	-$8.455M	-$19.83M	-$5.600M
YoY Change	2823.8%	-91.6%	51.06%	-40.42%	-50.51%	38.69%	1984.02%	-113.65%	121.85%	-57.36%	254.13%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	-$3.774M	$1.635M	$2.577M	$2.686M	$2.736M	$1.136M	$8.000K	$11.00K	$8.000K	$309.0K	$91.00K	$0.00
YoY Change	-330.83%	-36.55%	-4.06%	-1.83%	140.85%	14100.0%	-27.27%	37.5%	-97.41%	239.56%
% of Operating Profit	-4.66%	59.05%	7.82%	12.31%	7.47%	1.54%	0.01%	0.43%
Other Income/Expense, Net	-$15.75M	-$7.317M	-$10.28M	$183.0K	-$2.578M	-$1.045M	$76.00K	$14.00K	-$515.0K	$1.508M	-$333.0K	$0.00
YoY Change	115.29%	-28.8%	-5715.85%	-107.1%	146.7%	-1475.0%	442.86%	-102.72%	-134.15%	-552.85%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	$61.43M	-$4.548M	$22.68M	$22.00M	$34.04M	$72.95M	$53.43M	$2.574M	-$19.27M	-$6.947M	-$20.16M	-$5.500M
YoY Change	-1450.77%	-120.06%	3.09%	-35.37%	-53.34%	36.53%	1975.64%	-113.36%	177.41%	-65.55%	266.62%
Income Tax	$25.79M	$4.079M	$10.69M	$7.685M	$2.135M	$21.00M	-$28.03M	$3.000K	-$1.295M	-$899.0K	-$781.0K	-$400.0K
% Of Pretax Income	41.98%		47.13%	34.93%	6.27%	28.79%	-52.46%	0.12%
Net Earnings	$35.64M	-$8.627M	$11.99M	$14.31M	$31.90M	$51.94M	$81.45M	$2.571M	-$17.98M	-$6.048M	-$19.38M	-$5.200M
YoY Change	-513.14%	-171.96%	-16.24%	-55.14%	-38.58%	-36.23%	3068.14%	-114.3%	197.24%	-68.8%	272.75%
Net Earnings / Revenue	11.26%	-5.03%	6.38%	7.31%	14.96%	21.94%	42.99%	3.88%	-94.13%	-44.21%	-763.41%	-54.74%
Basic Earnings Per Share	$2.76	-$0.66	$0.89	$1.04	$2.16	$3.44	$5.24	$0.17	-$1.97	-$3.25
Diluted Earnings Per Share	$2.73	-$0.66	$0.87	$1.01	$2.09	$3.27	$4.96	$0.16	-$1.97	-$3.25	-$1.396M	-$374.1K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$55.32M	$97.66M	$103.2M	$109.8M	$78.80M	$114.7M	$52.80M	$79.10M	$42.70M	$10.50M	$6.600M	$12.60M
YoY Change	-43.35%	-5.37%	-6.01%	39.34%	-31.3%	117.23%	-33.25%	85.25%	306.67%	59.09%	-47.62%
Cash & Equivalents	$55.32M	$97.66M	$103.2M	$109.8M	$78.80M	$114.7M	$52.80M	$79.10M	$22.70M	$10.50M	$5.100M	$8.100M
Short-Term Investments								$0.00	$20.00M	$0.00	$1.500M	$4.500M
Other Short-Term Assets	$13.20M	$11.89M	$3.700M	$15.10M	$10.30M	$15.10M	$11.40M	$1.900M	$1.700M	$1.900M	$600.0K	$800.0K
YoY Change	11.02%	221.35%	-75.5%	46.6%	-31.79%	32.46%	500.0%	11.76%	-10.53%	216.67%	-25.0%
Inventory	$47.79M	$21.91M	$8.100M	$6.600M	$8.300M	$5.100M	$2.700M	$15.00M	$1.300M	$0.00	$100.0K	$1.100M
Prepaid Expenses
Receivables	$72.44M	$41.15M	$51.10M	$48.00M	$66.50M	$53.80M	$42.20M	$26.30M	$7.300M	$5.100M	$1.600M	$300.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$188.8M	$172.6M	$166.1M	$179.4M	$163.8M	$188.7M	$109.1M	$122.3M	$53.00M	$17.50M	$8.900M	$14.80M
YoY Change	9.36%	3.92%	-7.41%	9.52%	-13.2%	72.96%	-10.79%	130.75%	202.86%	96.63%	-39.86%
Property, Plant & Equipment	$1.168M	$1.636M	$2.100M	$5.900M	$2.400M	$6.800M	$3.300M	$2.200M	$300.0K	$400.0K	$500.0K	$700.0K
YoY Change	-28.61%	-22.1%	-64.41%	145.83%	-64.71%	106.06%	50.0%	633.33%	-25.0%	-20.0%	-28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$52.88M	$29.08M	$32.40M	$13.90M	$14.50M	$11.50M	$28.80M	$100.0K	$0.00	$200.0K	$100.0K	$100.0K
YoY Change	81.86%	-10.26%	133.09%	-4.14%	26.09%	-60.07%	28700.0%		-100.0%	100.0%	0.0%
Total Long-Term Assets	$217.4M	$81.13M	$87.10M	$75.20M	$74.80M	$81.40M	$105.2M	$2.300M	$400.0K	$600.0K	$500.0K	$800.0K
YoY Change	167.99%	-6.86%	15.82%	0.53%	-8.11%	-22.62%	4473.91%	475.0%	-33.33%	20.0%	-37.5%
Total Assets	$406.2M	$253.7M	$253.2M	$254.6M	$238.6M	$270.1M	$214.3M	$124.6M	$53.40M	$18.10M	$9.400M	$15.60M
YoY Change
Accounts Payable	$18.99M	$16.43M	$6.300M	$5.500M	$9.900M	$27.00M	$15.70M	$3.900M	$4.100M	$1.200M	$1.400M	$1.500M
YoY Change	15.59%	160.81%	14.55%	-44.44%	-63.33%	71.97%	302.56%	-4.88%	241.67%	-14.29%	-6.67%
Accrued Expenses	$85.84M	$32.34M	$23.80M	$28.40M	$23.50M	$15.40M	$23.50M	$23.90M	$9.700M	$3.100M	$1.300M	$1.800M
YoY Change	165.46%	35.87%	-16.2%	20.85%	52.6%	-34.47%	-1.67%	146.39%	212.9%	138.46%	-27.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$8.600M	$0.00
YoY Change										-100.0%
Long-Term Debt Due	$6.250M	$25.61M	$8.000M	$5.000M	$6.300M	$4.900M
YoY Change	-75.59%	220.09%	60.0%	-20.63%	28.57%
Total Short-Term Liabilities	$111.1M	$74.38M	$38.10M	$38.80M	$39.70M	$47.30M	$41.00M	$34.30M	$20.30M	$14.30M	$20.90M	$9.300M
YoY Change	49.36%	95.21%	-1.8%	-2.27%	-16.07%	15.37%	19.53%	68.97%	41.96%	-31.58%	124.73%
Long-Term Debt	$56.22M	$0.00	$25.10M	$33.60M	$38.20M	$42.90M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change		-100.0%	-25.3%	-12.04%	-10.96%
Other Long-Term Liabilities	$5.297M	$2.903M	$4.000M	$3.000M	$0.00	$700.0K	$22.10M		$0.00	$1.700M	$700.0K	$0.00
YoY Change	82.47%	-27.43%	33.33%		-100.0%	-96.83%			-100.0%	142.86%
Total Long-Term Liabilities	$61.51M	$2.903M	$29.10M	$36.60M	$38.20M	$43.60M	$22.10M	$0.00	$0.00	$1.700M	$700.0K	$0.00
YoY Change	2018.95%	-90.02%	-20.49%	-4.19%	-12.39%	97.29%			-100.0%	142.86%
Total Liabilities	$172.6M	$77.28M	$67.20M	$75.40M	$77.80M	$90.90M	$63.10M	$34.30M	$20.30M	$16.00M	$21.50M	$9.300M
YoY Change	123.35%	15.0%	-10.88%	-3.08%	-14.41%	44.06%	83.97%	68.97%	26.88%	-25.58%	131.18%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Basic Shares Outstanding	12.93M shares	13.05M shares	13.48M shares	13.75M shares	14.77M shares	15.10M shares	15.53M shares	15.25M shares	9.956M shares	3.044M shares
Diluted Shares Outstanding	13.07M shares	13.05M shares	13.77M shares	14.14M shares	15.28M shares	15.91M shares	16.43M shares	16.25M shares	9.956M shares	3.044M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $11.688 Million

About EAGLE PHARMACEUTICALS, INC.

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.

Industry: Pharmaceutical Preparations Peers: Aerovate Therapeutics, Inc. ALBIREO PHARMA, INC. Humacyte, Inc. ALX ONCOLOGY HOLDINGS INC Arcturus Therapeutics Holdings Inc. Celularity Inc CytoDyn Inc. Ocugen, Inc. MeiraGTx Holdings plc